Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 172 articles:
HTML format



Single Articles


    June 2020
  1. CASARIN S, Dondossola E
    An agent-based model of prostate Cancer bone metastasis progression and response to Radium223.
    BMC Cancer. 2020;20:605.
    PubMed     Abstract available


  2. CHOI JB, Myong JP, Lee Y, Kim I, et al
    Does increased body mass index lead to elevated prostate cancer risk? It depends on waist circumference.
    BMC Cancer. 2020;20:589.
    PubMed     Abstract available


  3. MEHDI A, Cheishvili D, Arakelian A, Bismar TA, et al
    DNA methylation signatures of Prostate Cancer in peripheral T-cells.
    BMC Cancer. 2020;20:588.
    PubMed     Abstract available


  4. KNAUL FM, Doubova SV, Gonzalez Robledo MC, Durstine A, et al
    Self-identity, lived experiences, and challenges of breast, cervical, and prostate cancer survivorship in Mexico: a qualitative study.
    BMC Cancer. 2020;20:577.
    PubMed     Abstract available


  5. BOU-DARGHAM MJ, Sha L, Sang QA, Zhang J, et al
    Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
    BMC Cancer. 2020;20:572.
    PubMed     Abstract available


  6. LIN E, Garmo H, Van Hemelrijck M, Adolfsson J, et al
    Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study.
    BMC Cancer. 2020;20:551.
    PubMed     Abstract available


  7. LI Q, Shi Y, Sa R, Hao J, et al
    Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.
    BMC Cancer. 2020;20:555.
    PubMed     Abstract available


    May 2020
  8. MEYER HJ, Wienke A, Surov A
    Discrimination between clinical significant and insignificant prostate cancer with apparent diffusion coefficient - a systematic review and meta analysis.
    BMC Cancer. 2020;20:482.
    PubMed     Abstract available


  9. TRAN MGB, Bibby BAS, Yang L, Lo F, et al
    Independence of HIF1a and androgen signaling pathways in prostate cancer.
    BMC Cancer. 2020;20:469.
    PubMed     Abstract available


  10. BERGHEN C, Joniau S, Rans K, Devos G, et al
    Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial.
    BMC Cancer. 2020;20:457.
    PubMed     Abstract available


  11. VUOLUKKA K, Auvinen P, Palmgren JE, Aaltomaa S, et al
    Incidence of subsequent primary cancers and radiation-induced subsequent primary cancers after low dose-rate brachytherapy monotherapy for prostate cancer in long-term follow-up.
    BMC Cancer. 2020;20:453.
    PubMed     Abstract available


  12. DUDKA I, Thysell E, Lundquist K, Antti H, et al
    Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status.
    BMC Cancer. 2020;20:437.
    PubMed     Abstract available


  13. MOORE C, Palau VE, Mahboob R, Lightner J, et al
    Upregulation of pERK and c-JUN by gamma-tocotrienol and not alpha-tocopherol are essential to the differential effect on apoptosis in prostate cancer cells.
    BMC Cancer. 2020;20:428.
    PubMed     Abstract available


  14. QIU C, Bai Y, Yin T, Miao X, et al
    Targeted imaging of orthotopic prostate cancer by using clinical transformable photoacoustic molecular probe.
    BMC Cancer. 2020;20:419.
    PubMed     Abstract available


  15. DE BRUYCKER A, Spiessens A, Dirix P, Koutsouvelis N, et al
    PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
    BMC Cancer. 2020;20:406.
    PubMed     Abstract available


  16. MILLER ET, You S, Cadaneanu RM, Kim M, et al
    Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
    BMC Cancer. 2020;20:398.
    PubMed     Abstract available


  17. WANG S, Zhou X, Liang C, Bao M, et al
    ALDH1A3 serves as a predictor for castration resistance in prostate cancer patients.
    BMC Cancer. 2020;20:387.
    PubMed     Abstract available


  18. WANG M, Wasserman E, Geyer N, Carroll RM, et al
    Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014.
    BMC Cancer. 2020;20:394.
    PubMed     Abstract available


    April 2020
  19. LI B, Lu Z, Wang S, Hou J, et al
    Pretreatment elevated prognostic nutritional index predicts a favorable prognosis in patients with prostate cancer.
    BMC Cancer. 2020;20:361.
    PubMed     Abstract available


  20. OEHUS AK, Kroeze SGC, Schmidt-Hegemann NS, Vogel MME, et al
    Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    BMC Cancer. 2020;20:362.
    PubMed     Abstract available


  21. ZHENG Z, Zhou Z, Yan W, Zhou Y, et al
    Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level < 4 ng/ml: a population-based study.
    BMC Cancer. 2020;20:340.
    PubMed     Abstract available


  22. CHEN JJ, Zhu ZS, Zhu YY, Shi HQ, et al
    Applied anatomy of pelvic lymph nodes and its clinical significance for prostate cancer:a single-center cadaveric study.
    BMC Cancer. 2020;20:330.
    PubMed     Abstract available


  23. LEHTONEN M, Heiskanen L, Reinikainen P, Kellokumpu-Lehtinen PL, et al
    Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer.
    BMC Cancer. 2020;20:324.
    PubMed     Abstract available


  24. MATSUDA Y, Narita S, Nara T, Mingguo H, et al
    Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer.
    BMC Cancer. 2020;20:302.
    PubMed     Abstract available


  25. CHEN C, Cai Z, Zhuo Y, Xi M, et al
    Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
    BMC Cancer. 2020;20:289.
    PubMed     Abstract available


    March 2020
  26. SONG H, Jin S, Xiang P, Hu S, et al
    Prognostic value of the bone scan index in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:238.
    PubMed     Abstract available


    February 2020
  27. ZHOU X, Ning Q, Jin K, Zhang T, et al
    Development and validation of a preoperative nomogram for predicting survival of patients with locally advanced prostate cancer after radical prostatectomy.
    BMC Cancer. 2020;20:97.
    PubMed     Abstract available


  28. BUWENGE M, Scirocco E, Deodato F, Macchia G, et al
    Radiotherapy of prostate cancer: impact of treatment characteristics on the incidence of second tumors.
    BMC Cancer. 2020;20:90.
    PubMed     Abstract available


    January 2020
  29. KAWAMURA H, Kubo N, Sato H, Mizukami T, et al
    Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study "GUNMA0702".
    BMC Cancer. 2020;20:75.
    PubMed     Abstract available


    December 2019
  30. LIAO KM, Huang YB, Chen CY, Kuo CC, et al
    Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan.
    BMC Cancer. 2019;19:1263.
    PubMed     Abstract available


  31. ZHEN L, Liu X, Yegang C, Yongjiao Y, et al
    Accuracy of multiparametric magnetic resonance imaging for diagnosing prostate Cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:1244.
    PubMed     Abstract available


  32. ZONI E, Minoli M, Bovet C, Wehrhan A, et al
    Preoperative plasma fatty acid metabolites inform risk of prostate cancer progression and may be used for personalized patient stratification.
    BMC Cancer. 2019;19:1216.
    PubMed     Abstract available


  33. ZHOU J, Xia S, Li T, Liu R, et al
    Could aspirin be a lifesaver for prostate cancer patients in prostate cancer-specific mortality?: an update systematic review and meta-analysis.
    BMC Cancer. 2019;19:1186.
    PubMed     Abstract available


  34. RUI X, Shao S, Wang L, Leng J, et al
    Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram.
    BMC Cancer. 2019;19:1179.
    PubMed     Abstract available


    November 2019
  35. HUANG Z, Li G, Zhang Z, Gu R, et al
    beta2AR-HIF-1alpha-CXCL12 signaling of osteoblasts activated by isoproterenol promotes migration and invasion of prostate cancer cells.
    BMC Cancer. 2019;19:1142.
    PubMed     Abstract available


  36. GUO W, Sun YC, Bi JQ, He XY, et al
    Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials.
    BMC Cancer. 2019;19:1063.
    PubMed     Abstract available


    October 2019
  37. SEMAAN L, Mander N, Cher ML, Chinni SR, et al
    TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
    BMC Cancer. 2019;19:972.
    PubMed     Abstract available


  38. DONNELLY DW, Vis LC, Kearney T, Sharp L, et al
    Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study.
    BMC Cancer. 2019;19:947.
    PubMed     Abstract available


  39. WEIDEMANN SA, Sauer C, Luebke AM, Moller-Koop C, et al
    High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
    BMC Cancer. 2019;19:944.
    PubMed     Abstract available


    September 2019
  40. MARVASO G, Ciardo D, Corrao G, Gandini S, et al
    Radioablation +/- hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159).
    BMC Cancer. 2019;19:903.
    PubMed     Abstract available


  41. REN ZJ, Cao DH, Zhang Q, Ren PW, et al
    First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:871.
    PubMed     Abstract available


    August 2019
  42. LAWRANCE S, Bui C, Mahindra V, Arcorace M, et al
    Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
    BMC Cancer. 2019;19:850.
    PubMed     Abstract available


  43. PUENTE J, Gonzalez-Del-Alba A, Sala-Gonzalez N, Mendez-Vidal MJ, et al
    Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
    BMC Cancer. 2019;19:766.
    PubMed     Abstract available


    July 2019
  44. YANAI Y, Kosaka T, Hongo H, Oya M, et al
    Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report.
    BMC Cancer. 2019;19:720.
    PubMed     Abstract available


  45. ZHU Y, Wang Y, Qian Z, Pan J, et al
    Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases.
    BMC Cancer. 2019;19:676.
    PubMed     Abstract available


  46. ADLARD KN, Jenkins DG, Salisbury CE, Bolam KA, et al
    Peer support for the maintenance of physical activity and health in cancer survivors: the PEER trial - a study protocol of a randomised controlled trial.
    BMC Cancer. 2019;19:656.
    PubMed     Abstract available


    June 2019
  47. ENDEPOLS H, Morgenroth A, Zlatopolskiy BD, Krapf P, et al
    Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents.
    BMC Cancer. 2019;19:633.
    PubMed     Abstract available


  48. KIENER M, Chen L, Krebs M, Grosjean J, et al
    miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo.
    BMC Cancer. 2019;19:627.
    PubMed     Abstract available


  49. BECKMANN K, Russell B, Josephs D, Garmo H, et al
    Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study.
    BMC Cancer. 2019;19:612.
    PubMed     Abstract available


  50. KAPOOR R, Deek MP, McIntyre R, Raman N, et al
    A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
    BMC Cancer. 2019;19:572.
    PubMed     Abstract available


  51. KOSAKA T, Hongo H, Oya M
    Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    BMC Cancer. 2019;19:562.
    PubMed     Abstract available


    May 2019
  52. SCHIFF JP, Cotogno P, Feibus A, Steinwald P, et al
    Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer.
    BMC Cancer. 2019;19:524.
    PubMed     Abstract available


  53. KANAN AD, Corey E, Vencio RZN, Ishwar A, et al
    Lineage relationship between prostate adenocarcinoma and small cell carcinoma.
    BMC Cancer. 2019;19:518.
    PubMed     Abstract available


  54. WERUTSKY G, Maluf FC, Cronemberger EH, Carrera Souza V, et al
    The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
    BMC Cancer. 2019;19:487.
    PubMed     Abstract available


  55. BURM R, Thewes B, Rodwell L, Kievit W, et al
    Long-term efficacy and cost-effectiveness of blended cognitive behavior therapy for high fear of recurrence in breast, prostate and colorectal Cancer survivors: follow-up of the SWORD randomized controlled trial.
    BMC Cancer. 2019;19:462.
    PubMed     Abstract available


  56. GEORGESCU C, Corbin JM, Thibivilliers S, Webb ZD, et al
    A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    BMC Cancer. 2019;19:423.
    PubMed     Abstract available


    April 2019
  57. ZHANG Y, Li F, Liu L, Jiang H, et al
    Salinomycin triggers endoplasmic reticulum stress through ATP2A3 upregulation in PC-3 cells.
    BMC Cancer. 2019;19:381.
    PubMed     Abstract available


  58. FRANKLAND J, Brodie H, Cooke D, Foster C, et al
    Follow-up care after treatment for prostate cancer: evaluation of a supported self-management and remote surveillance programme.
    BMC Cancer. 2019;19:368.
    PubMed     Abstract available


  59. DULSKAS A, Cereska V, Zurauskas E, Stratilatovas E, et al
    Prostate cancer solitary metastasis to anal canal: case report and review of literature.
    BMC Cancer. 2019;19:374.
    PubMed     Abstract available


  60. TIWARI A, Mukherjee B, Hassan MK, Pattanaik N, et al
    Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion.
    BMC Cancer. 2019;19:346.
    PubMed     Abstract available


  61. IGUCHI T, Tamada S, Kato M, Yasuda S, et al
    Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study).
    BMC Cancer. 2019;19:339.
    PubMed     Abstract available


  62. NEIL-SZTRAMKO SE, Medysky ME, Campbell KL, Bland KA, et al
    Attention to the principles of exercise training in exercise studies on prostate cancer survivors: a systematic review.
    BMC Cancer. 2019;19:321.
    PubMed     Abstract available


  63. PARIKH NR, Huiza C, Patel JS, Tsai S, et al
    Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
    BMC Cancer. 2019;19:291.
    PubMed     Abstract available


    March 2019
  64. MAMIDI TKK, Wu J, Hicks C
    Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer.
    BMC Cancer. 2019;19:229.
    PubMed     Abstract available


  65. SCHROEDER C, Grell J, Hube-Magg C, Kluth M, et al
    Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer.
    BMC Cancer. 2019;19:193.
    PubMed     Abstract available


  66. HUMMEL S, Kohlmann W, Kollmeyer TM, Jenkins R, et al
    The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database.
    BMC Cancer. 2019;19:190.
    PubMed     Abstract available


    February 2019
  67. TERADA N, Kamoto T, Tsukino H, Mukai S, et al
    The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
    BMC Cancer. 2019;19:156.
    PubMed     Abstract available


  68. CHUNG WS, Lin CL
    Sleep disorders associated with risk of prostate cancer: a population-based cohort study.
    BMC Cancer. 2019;19:146.
    PubMed     Abstract available


    January 2019
  69. CALAIS J, Czernin J, Fendler WP, Elashoff D, et al
    Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
    BMC Cancer. 2019;19:97.
    PubMed     Abstract available


  70. LI T, Sun X, Chen L
    Free testosterone value before radical prostatectomy is related to oncologic outcomes and post-operative erectile function.
    BMC Cancer. 2019;19:87.
    PubMed     Abstract available


  71. BOEGEMANN M, Khaksar S, Bera G, Birtle A, et al
    Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
    BMC Cancer. 2019;19:60.
    PubMed     Abstract available


  72. QIU X, Wang W, Li B, Cheng B, et al
    Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells.
    BMC Cancer. 2019;19:27.
    PubMed     Abstract available


  73. CALAIS J, Czernin J, Fendler WP, Elashoff D, et al
    Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
    BMC Cancer. 2019;19:18.
    PubMed     Abstract available


  74. HEIDENREICH A, Gillessen S, Heinrich D, Keizman D, et al
    Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
    BMC Cancer. 2019;19:12.
    PubMed     Abstract available


  75. ALIBHAI SMH, Santa Mina D, Ritvo P, Tomlinson G, et al
    A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.
    BMC Cancer. 2019;19:2.
    PubMed     Abstract available


    December 2018
  76. TAKUWA H, Tsuji W, Shintaku M, Yotsumoto F, et al
    Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report.
    BMC Cancer. 2018;18:1282.
    PubMed     Abstract available


  77. CULTRARA CN, Kozuch SD, Ramasundaram P, Heller CJ, et al
    GRP78 modulates cell adhesion markers in prostate Cancer and multiple myeloma cell lines.
    BMC Cancer. 2018;18:1263.
    PubMed     Abstract available


  78. BOSSAN A, Ottman R, Andl T, Hasan MF, et al
    Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer.
    BMC Cancer. 2018;18:1257.
    PubMed     Abstract available


  79. MAI Z, Zhou Z, Yan W, Xiao Y, et al
    The transverse and vertical distribution of prostate cancer in biopsy and radical prostatectomy specimens.
    BMC Cancer. 2018;18:1205.
    PubMed     Abstract available


    November 2018
  80. MARTINEZ-GONZALEZ NA, Neuner-Jehle S, Plate A, Rosemann T, et al
    Correction to: The effects of shared decision-making compared to usual care for prostate cancer screening decisions: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:1196.
    PubMed     Abstract available


  81. ALVAREZ CS, Villamor E, Meza R, Rozek LS, et al
    Differences in prostate tumor characteristics and survival among religious groups in Songkhla, Thailand.
    BMC Cancer. 2018;18:1175.
    PubMed     Abstract available


  82. GHOSHAL A, Garmo H, Hammar N, Jungner I, et al
    Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival?
    BMC Cancer. 2018;18:1169.
    PubMed     Abstract available


  83. JOACHIM C, Veronique-Baudin J, Ulric-Gervaise S, Macni J, et al
    Pattern of care of prostate cancer patients across the Martinique: results of a population-based study in the Caribbean.
    BMC Cancer. 2018;18:1130.
    PubMed     Abstract available


  84. GOTARDELO DR, Courrol LC, Bellini MH, de Oliveira Silva FR, et al
    Porphyrins are increased in the faeces of patients with prostate cancer: a case-control study.
    BMC Cancer. 2018;18:1090.
    PubMed     Abstract available


  85. NI J, Cozzi P, Beretov J, Duan W, et al
    Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo.
    BMC Cancer. 2018;18:1092.
    PubMed     Abstract available


  86. VAN DE WIEL HJ, Stuiver MM, May AM, van Grinsven S, et al
    (Cost-)effectiveness of an internet-based physical activity support program (with and without physiotherapy counselling) on physical activity levels of breast and prostate cancer survivors: design of the PABLO trial.
    BMC Cancer. 2018;18:1073.
    PubMed     Abstract available


  87. ZEIGLER-JOHNSON C, Hudson A, Glanz K, Spangler E, et al
    Performance of prostate cancer recurrence nomograms by obesity status: a retrospective analysis of a radical prostatectomy cohort.
    BMC Cancer. 2018;18:1061.
    PubMed     Abstract available


  88. CHUNG DY, Koh DH, Goh HJ, Kim MS, et al
    Clinical significance and predictors of oncologic outcome after radical prostatectomy for invisible prostate cancer on multiparametric MRI.
    BMC Cancer. 2018;18:1057.
    PubMed     Abstract available


    October 2018
  89. ALIBHAI SMH, Ritvo P, Santa Mina D, Sabiston C, et al
    Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT.
    BMC Cancer. 2018;18:1031.
    PubMed     Abstract available


  90. MARTINEZ-GONZALEZ NA, Neuner-Jehle S, Plate A, Rosemann T, et al
    The effects of shared decision-making compared to usual care for prostate cancer screening decisions: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:1015.
    PubMed     Abstract available


  91. IVANOVIC RF, Viana NI, Morais DR, Moura C, et al
    miR-618: possible control over TIMP-1 and its expression in localized prostate cancer.
    BMC Cancer. 2018;18:992.
    PubMed     Abstract available


  92. MUSSAWY H, Viezens L, Schroeder M, Hettenhausen S, et al
    The bone microenvironment promotes tumor growth and tissue perfusion compared with striated muscle in a preclinical model of prostate cancer in vivo.
    BMC Cancer. 2018;18:979.
    PubMed     Abstract available


  93. JIVIDEN K, Kedzierska KZ, Yang CS, Szlachta K, et al
    Genomic analysis of DNA repair genes and androgen signaling in prostate cancer.
    BMC Cancer. 2018;18:960.
    PubMed     Abstract available


    August 2018
  94. PACYNA JE, Kim S, Yost K, Sedlacek H, et al
    The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD.
    BMC Cancer. 2018;18:788.
    PubMed     Abstract available


    July 2018
  95. ULLRICH A, Rath HM, Otto U, Kerschgens C, et al
    Return to work in prostate cancer survivors - findings from a prospective study on occupational reintegration following a cancer rehabilitation program.
    BMC Cancer. 2018;18:751.
    PubMed     Abstract available


  96. ORTELLI L, Spitale A, Mazzucchelli L, Bordoni A, et al
    Quality indicators of clinical cancer care for prostate cancer: a population-based study in southern Switzerland.
    BMC Cancer. 2018;18:733.
    PubMed     Abstract available


    June 2018
  97. GREGOIRE C, Nicolas H, Bragard I, Delevallez F, et al
    Efficacy of a hypnosis-based intervention to improve well-being during cancer: a comparison between prostate and breast cancer patients.
    BMC Cancer. 2018;18:677.
    PubMed     Abstract available


  98. GREASLEY RU, Turner R, Collins K, Brown J, et al
    Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems.
    BMC Cancer. 2018;18:667.
    PubMed     Abstract available


    May 2018
  99. KASHIWABARA T, Suda S
    Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level >/= 50 ng/mL.
    BMC Cancer. 2018;18:619.
    PubMed     Abstract available


  100. HEINRICH MC, Gobel C, Kluth M, Bernreuther C, et al
    PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.
    BMC Cancer. 2018;18:612.
    PubMed     Abstract available


  101. MOSAAD E, Chambers K, Futrega K, Clements J, et al
    Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures.
    BMC Cancer. 2018;18:592.
    PubMed     Abstract available


  102. RICHARDSON M, Sidhom M, Gallagher S, Grand M, et al
    PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol.
    BMC Cancer. 2018;18:588.
    PubMed     Abstract available


  103. PASQUIER D, Bogart E, Bonodeau F, Lacornerie T, et al
    BioPro-RCMI-1505 trial: multicenter study evaluating the use of a biodegradable balloon for the treatment of intermediate risk prostate cancer by intensity modulated radiotherapy; study protocol.
    BMC Cancer. 2018;18:566.
    PubMed     Abstract available


  104. PARK JW, Koh DH, Jang WS, Cho KS, et al
    Predictors of adverse pathologic features after radical prostatectomy in low-risk prostate cancer.
    BMC Cancer. 2018;18:545.
    PubMed     Abstract available


  105. UEMURA K, Miyoshi Y, Kawahara T, Ryosuke J, et al
    Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel.
    BMC Cancer. 2018;18:501.
    PubMed     Abstract available


    April 2018
  106. RYE MB, Bertilsson H, Andersen MK, Rise K, et al
    Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized.
    BMC Cancer. 2018;18:478.
    PubMed     Abstract available


  107. KOO KC, Lee JS, Kim JW, Han KS, et al
    Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis.
    BMC Cancer. 2018;18:468.
    PubMed     Abstract available


  108. JONES DZ, Schmidt ML, Suman S, Hobbing KR, et al
    Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells.
    BMC Cancer. 2018;18:421.
    PubMed     Abstract available


  109. DAWSON JK, Dorff TB, Todd Schroeder E, Lane CJ, et al
    Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
    BMC Cancer. 2018;18:368.
    PubMed     Abstract available


  110. TOSCO L, Laenen A, Gevaert T, Salmon I, et al
    Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
    BMC Cancer. 2018;18:354.
    PubMed     Abstract available


  111. BOWLER E, Porazinski S, Uzor S, Thibault P, et al
    Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells.
    BMC Cancer. 2018;18:355.
    PubMed     Abstract available


    March 2018
  112. LIANG W, Song L, Peng Z, Zou Y, et al
    Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:279.
    PubMed     Abstract available


  113. KIM M, Song C, Jeong IG, Choi SK, et al
    Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study.
    BMC Cancer. 2018;18:271.
    PubMed     Abstract available


  114. CARAM MEV, Estes JP, Griggs JJ, Lin P, et al
    Temporal and geographic variation in the systemic treatment of advanced prostate cancer.
    BMC Cancer. 2018;18:258.
    PubMed     Abstract available


    February 2018
  115. BOSCO C, Garmo H, Hammar N, Walldius G, et al
    Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort.
    BMC Cancer. 2018;18:205.
    PubMed     Abstract available


  116. IBRAHIM M, Yadav S, Ogunleye F, Zakalik D, et al
    Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    BMC Cancer. 2018;18:179.
    PubMed     Abstract available


  117. JIMENEZ-MENDOZA E, Vazquez-Salas RA, Barrientos-Gutierrez T, Reynales-Shigematsu LM, et al
    Smoking and prostate cancer: a life course analysis.
    BMC Cancer. 2018;18:160.
    PubMed     Abstract available


  118. FORT RS, Matho C, Geraldo MV, Ottati MC, et al
    Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth.
    BMC Cancer. 2018;18:127.
    PubMed     Abstract available


    January 2018
  119. LANGE M, Laviec H, Castel H, Heutte N, et al
    Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol.
    BMC Cancer. 2018;18:110.
    PubMed     Abstract available


  120. MACIEL-SILVA P, Caldeira I, de Assis Santos I, Carreira ACO, et al
    FAM3B/PANDER inhibits cell death and increases prostate tumor growth by modulating the expression of Bcl-2 and Bcl-XL cell survival genes.
    BMC Cancer. 2018;18:90.
    PubMed     Abstract available


  121. SANGHERA S, Coast J, Martin RM, Donovan JL, et al
    Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models.
    BMC Cancer. 2018;18:84.
    PubMed     Abstract available


  122. GUERTIN MH, Robitaille K, Pelletier JF, Duchesne T, et al
    Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-c
    BMC Cancer. 2018;18:64.
    PubMed     Abstract available


  123. CHEN CB, Eskin M, Eurich DT, Majumdar SR, et al
    Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:65.
    PubMed     Abstract available


  124. HEUMANN A, Heinemann N, Hube-Magg C, Lang DS, et al
    High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.
    BMC Cancer. 2018;18:37.
    PubMed     Abstract available


  125. DEPCZYNSKI J, Dobbins T, Armstrong B, Lower T, et al
    Comparison of cancer incidence in Australian farm residents 45 years and over, compared to rural non-farm and urban residents - a data linkage study.
    BMC Cancer. 2018;18:33.
    PubMed     Abstract available


  126. PARK SY, Park JW, Lee GW, Li L, et al
    Inhibition of neddylation facilitates cell migration through enhanced phosphorylation of caveolin-1 in PC3 and U373MG cells.
    BMC Cancer. 2018;18:30.
    PubMed     Abstract available


  127. BOTTCHER R, Kweldam CF, Livingstone J, Lalonde E, et al
    Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
    BMC Cancer. 2018;18:8.
    PubMed     Abstract available


  128. PESTOVA K, Koch AJ, Quesenberry CP, Shan J, et al
    Identification of fluorescence in situ hybridization assay markers for prediction of disease progression in prostate cancer patients on active surveillance.
    BMC Cancer. 2018;18:2.
    PubMed     Abstract available


    December 2017
  129. YANG KQ, Liu Y, Huang QH, Mo N, et al
    Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenetic factors and promote prostate cancer growth.
    BMC Cancer. 2017;17:878.
    PubMed     Abstract available


  130. DAMODARAN S, Damaschke N, Gawdzik J, Yang B, et al
    Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes.
    BMC Cancer. 2017;17:874.
    PubMed     Abstract available


  131. BEEBE-DIMMER JL, Yee C, Paskett E, Schwartz AG, et al
    Family history of prostate and colorectal cancer and risk of colorectal cancer in the Women's health initiative.
    BMC Cancer. 2017;17:848.
    PubMed     Abstract available


  132. EGGLY S, Hamel LM, Heath E, Manning MA, et al
    Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials.
    BMC Cancer. 2017;17:807.
    PubMed     Abstract available


    November 2017
  133. KANG YJ, Jang WS, Kwon JK, Yoon CY, et al
    Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.
    BMC Cancer. 2017;17:789.
    PubMed     Abstract available


  134. SAIFUDDIN SR, Devlies W, Santaolalla A, Cahill F, et al
    King's Health Partners' Prostate Cancer Biobank (KHP PCaBB).
    BMC Cancer. 2017;17:784.
    PubMed     Abstract available


  135. TSAI HK, Lehrer J, Alshalalfa M, Erho N, et al
    Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    BMC Cancer. 2017;17:759.
    PubMed     Abstract available


  136. CINDOLO L, Natoli C, De Nunzio C, De Tursi M, et al
    Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study.
    BMC Cancer. 2017;17:753.
    PubMed     Abstract available


  137. ENDZELINS E, Berger A, Melne V, Bajo-Santos C, et al
    Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients.
    BMC Cancer. 2017;17:730.
    PubMed     Abstract available


  138. ERNST J, Mehnert A, Dietz A, Hornemann B, et al
    Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients.
    BMC Cancer. 2017;17:741.
    PubMed     Abstract available


  139. JIANN BP
    Does hair dye use really increase the risk of prostate cancer?
    BMC Cancer. 2017;17:724.
    PubMed     Abstract available


    October 2017
  140. KIRKMAN M, Young K, Evans S, Millar J, et al
    Men's perceptions of prostate cancer diagnosis and care: insights from qualitative interviews in Victoria, Australia.
    BMC Cancer. 2017;17:704.
    PubMed     Abstract available


  141. IZUMI K, Mizokami A, Namiki M, Inoue S, et al
    Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial.
    BMC Cancer. 2017;17:677.
    PubMed     Abstract available


  142. WITTMANN D, Mehta A, Northouse L, Dunn R, et al
    TrueNTH sexual recovery study protocol: a multi-institutional collaborative approach to developing and testing a web-based intervention for couples coping with the side-effects of prostate cancer treatment in a randomized controlled trial.
    BMC Cancer. 2017;17:664.
    PubMed     Abstract available


    September 2017
  143. ABHYANKAR N, Hoskins KF, Abern MR, Calip GS, et al
    Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis.
    BMC Cancer. 2017;17:659.
    PubMed     Abstract available


  144. FRANKLAND J, Brodie H, Cooke D, Foster C, et al
    Follow-up care after treatment for prostate cancer: protocol for an evaluation of a nurse-led supported self-management and remote surveillance programme.
    BMC Cancer. 2017;17:656.
    PubMed     Abstract available


  145. PASCALE M, Azinwi CN, Marongiu B, Pesce G, et al
    The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression.
    BMC Cancer. 2017;17:651.
    PubMed     Abstract available


  146. SONG W, Soni V, Soni S, Khera M, et al
    Testosterone inhibits the growth of prostate cancer xenografts in nude mice.
    BMC Cancer. 2017;17:635.
    PubMed     Abstract available


  147. GONNISSEN A, Isebaert S, Perneel C, McKee CM, et al
    Tissue microarray analysis indicates hedgehog signaling as a potential prognostic factor in intermediate-risk prostate cancer.
    BMC Cancer. 2017;17:634.
    PubMed     Abstract available


  148. MITRA R, Le TT, Gorjala P, Goodman OB Jr, et al
    Positive regulation of prostate cancer cell growth by lipid droplet forming and processing enzymes DGAT1 and ABHD5.
    BMC Cancer. 2017;17:631.
    PubMed     Abstract available


  149. WANG H, Gu L, Wu Y, Feng D, et al
    The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score >/= 7 prostate cancer from group of biopsy-based Gleason score </= 6.
    BMC Cancer. 2017;17:629.
    PubMed     Abstract available


  150. TANAKA N, Nakai Y, Miyake M, Anai S, et al
    Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012.
    BMC Cancer. 2017;17:616.
    PubMed     Abstract available


    August 2017
  151. KINNUNEN PTT, Murtola TJ, Talala K, Taari K, et al
    Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.
    BMC Cancer. 2017;17:585.
    PubMed     Abstract available


  152. TANAKA N, Asakawa I, Nakai Y, Miyake M, et al
    Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
    BMC Cancer. 2017;17:573.
    PubMed     Abstract available


  153. QIU J, Peng S, Si-Tu J, Hu C, et al
    Erratum to: Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer.
    BMC Cancer. 2017;17:569.
    PubMed    


  154. LANGE M, Laviec H, Castel H, Heutte N, et al
    Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol.
    BMC Cancer. 2017;17:549.
    PubMed     Abstract available


  155. BECKMANN KR, Vincent AD, O'Callaghan ME, Cohen P, et al
    Oncological outcomes in an Australian cohort according to the new prostate cancer grading groupings.
    BMC Cancer. 2017;17:537.
    PubMed     Abstract available


  156. LAO C, Edlin R, Rouse P, Brown C, et al
    The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer.
    BMC Cancer. 2017;17:529.
    PubMed     Abstract available


    July 2017
  157. JACOBSEN F, Taskin B, Melling N, Sauer C, et al
    Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer.
    BMC Cancer. 2017;17:504.
    PubMed     Abstract available


  158. CRAWLEY D, Chandra A, Loda M, Gillett C, et al
    Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.
    BMC Cancer. 2017;17:494.
    PubMed     Abstract available


  159. LANGIUS-EKLOF A, Crafoord MT, Christiansen M, Fjell M, et al
    Effects of an interactive mHealth innovation for early detection of patient-reported symptom distress with focus on participatory care: protocol for a study based on prospective, randomised, controlled trials in patients with prostate and breast cance
    BMC Cancer. 2017;17:466.
    PubMed     Abstract available


  160. GRANT DJ, Chen Z, Howard LE, Wiggins E, et al
    UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression.
    BMC Cancer. 2017;17:463.
    PubMed     Abstract available


    June 2017
  161. RADWAN N, Phillips R, Ross A, Rowe SP, et al
    A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
    BMC Cancer. 2017;17:453.
    PubMed     Abstract available


  162. GOLSTEIJN RHJ, Bolman C, Volders E, Peels DA, et al
    Development of a computer-tailored physical activity intervention for prostate and colorectal cancer patients and survivors: OncoActive.
    BMC Cancer. 2017;17:446.
    PubMed     Abstract available


    May 2017
  163. TAN G, Qiu M, Chen L, Zhang S, et al
    JS-K, a nitric oxide pro-drug, regulates growth and apoptosis through the ubiquitin-proteasome pathway in prostate cancer cells.
    BMC Cancer. 2017;17:376.
    PubMed     Abstract available


  164. MANCARELLA C, Casanova-Salas I, Calatrava A, Garcia-Flores M, et al
    Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
    BMC Cancer. 2017;17:367.
    PubMed     Abstract available


  165. QIU J, Peng S, Si-Tu J, Hu C, et al
    Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer.
    BMC Cancer. 2017;17:360.
    PubMed     Abstract available


  166. HABL G, Straube C, Schiller K, Duma MN, et al
    Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
    BMC Cancer. 2017;17:361.
    PubMed     Abstract available


  167. KAWAKAMI K, Fujita Y, Matsuda Y, Arai T, et al
    Gamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancer.
    BMC Cancer. 2017;17:316.
    PubMed     Abstract available


    April 2017
  168. KIRBY MK, Ramaker RC, Roberts BS, Lasseigne BN, et al
    Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns.
    BMC Cancer. 2017;17:273.
    PubMed     Abstract available


  169. NGOLLO M, Lebert A, Daures M, Judes G, et al
    Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression.
    BMC Cancer. 2017;17:261.
    PubMed     Abstract available


    March 2017
  170. BERNTSEN S, Aaronson NK, Buffart L, Borjeson S, et al
    Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome.
    BMC Cancer. 2017;17:218.
    PubMed     Abstract available


  171. KEALL P, Nguyen DT, O'Brien R, Booth J, et al
    Stereotactic prostate adaptive radiotherapy utilising kilovoltage intrafraction monitoring: the TROG 15.01 SPARK trial.
    BMC Cancer. 2017;17:180.
    PubMed     Abstract available


    February 2017
  172. MEDENWALD D, Vordermark D, Dietzel CT
    Cancer mortality in former East and West Germany: a story of unification?
    BMC Cancer. 2017;17:94.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: